Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregnenolone for Co-Occurring Cannabis Use Disorder and Depression
NCT07685964Phase 2Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pregnenolone in cannabis use disorder (CUD), major depressive disorder (MDD), sponsored by UT Southwestern Medical Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pregnenolone
03
Conditions
cannabis use disorder (CUD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07685964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685964.